@RPtash

Director of New Technology @C2iGenomics 🧬 💻

Joined January 2011
  • Tweets46
  • Following157
  • Followers110
7Media
Recently published #CancerResearch: @ahmetz @RPtash @MEArcila @MSKPathology develop and test the #mskimpact Heme sequencing panel and platform to profile #BloodCancers in the clinic @NatResCancer nature.com/articles/s41467-0…

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal...

Nature Communications - Targeted sequencing panels such as MSK-IMPACT have been successfully used to profile solid tumours in clinical settings. Here, the authors develop and implement the...

nature.com
1
9
6,188
Ryan N. Ptashkin retweeted
Ahmet Zehir@ahmetz3 Oct 2023
By now, i’m sure most of you saw that FDA is planning to regulate LDTs (public-inspection.federalreg…). A paper, suggesting clinical labs failed PT testing, is cited in the FDA doc as one of the reasons. What if the analyses in this paper were flawed? 🧵👇🏼 doi.org/10.5858/arpa.2023-03…
3
15
1
26
6,297
Ryan N. Ptashkin retweeted
Paz Polak@PolakPaz6 Apr 2023
Thrilled to be attending #AACR2023 in Orlando! 😃 We're proud to present 3 posters and share how @C2iGenomics technology is making a real difference in MRD testing for cancer patients. I'd love to meet you over coffee at booth 1161 and chat more about it! ☕️ #MRD #WGS
4
7
2
22
2,959
Ryan N. Ptashkin retweeted
Dan Landau@landau_lab18 Nov 2022
🔥Extra-hot pre-print before this hellsite goes up in smoke 🔥 New horizons open up when sequencing costs go ↘️ @UltimaGenomics Interested in deep cfDNA WGS for ultra-sensitive cancer detection? Duplex sequencing at genome scale? biorxiv.org/content/10.1101/… Check out 🪡👇

Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring

Circulating cell-free DNA (ccfDNA) sequencing for low-burden cancer monitoring is limited by sparsity of circulating tumor DNA (ctDNA), the abundance of genomic material within a plasma sample, and...

biorxiv.org
8
82
18
294
Happy to share our @medrxivpreprint on MSK-IMPACT Heme: a prospective clinical sequencing effort @MSKCancerCenter to guide the diagnosis, prognosis, & therapy selection for patients across hematologic malignancies 🧵(1/n) medrxiv.org/content/10.1101/…

Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal...

Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease...

medrxiv.org
1
6
29
more replies
By removing rare germline variants from reporting through genotyping of candidate variants in matched normal tissue(s), we can better identify appropriate markers for MRD assessment and prevent false positive calls (6/n)
1
2
With continued testing and data sharing, it is our belief that broad genomic assessment will support identifying novel drug targets for and improving noninvasive monitoring for response in all patients with hematologic cancers (7/n)
2
Ryan N. Ptashkin retweeted
Elizabeth McKenna@ElizSMcKenna4 Apr 2022
This month's cover of @CD_AACR features work on mosaic variants in cancer susceptibility genes by @FresiaPareja @RPtash David Brown, Jorge Reis-Filho, Diana Mandelker and colleagues @MSKPathology @sloan_kettering cancerdiscovery.aacrjournals…
Cancer Discovery@CD_AACR4 Apr 2022
Check out the April issue of Cancer Discovery! bit.ly/3DHS1A3
1
8
22
Ryan N. Ptashkin retweeted
Elizabeth McKenna@ElizSMcKenna3 Jan 2022
Now online in @CD_AACR: Cancer Causative Mutations Occurring in Early #Embryogenesis by @FresiaPareja @RPtash David Brown, Jorge Reis-Filho, Diana Mandelker and colleagues @MSKPathology @sloan_kettering cancerdiscovery.aacrjournals…

Cancer-Causative Mutations Occurring in Early Embryogenesis

Mosaic variants affecting cancer susceptibility genes, which can be detected through the analysis of tumor/normal sequencing data, may arise in early embryogenesis and contribute to the development...

aacrjournals.org
24
2
59
Ryan N. Ptashkin retweeted
Ahmet Zehir@ahmetz18 Sep 2020
It's Friday and it's time for a new preprint biorxiv.org/content/10.1101/… : MSI status for cancer pts is critical as it is the first tissue-agnostic biomarker for treatment with pembrolizumab. We've been using NGS data from #MSKimpact + MSISensor to detect MSI status but 🧵 (1/n)

MiMSI - a deep multiple instance learning framework improves microsatellite instability detection...

Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Recent work has demonstrated...

biorxiv.org
2
15
2
47
The head of the United States Food and Drug Administration (!) @SteveFDA does not understand the difference between relative and absolute risk reduction -- a basic, fundamental concept in medicine, statistics and clinical trial interpretation. It just gets worse and worse.😢
U.S. FDA
@FDA23 Aug 2020
"A 35 percent improvement in survival is a pretty substantial clinical benefit," FDA Commissioner @SteveFDA said in relation to the convalescent plasma emergency use authorization issued today.
30
100
18
374
Come visit our @OncoKB poster (#2148) about annotation of the oncogenic effect and diagnostic, prognostic, and therapeutic implications of somatic genomic variants in hematologic malignancies #ASH2019 @sloan_kettering @ritikakundra10 @HongxinZhang @CDebyaniPhD
1
13
2
38
Ryan N. Ptashkin retweeted
Ahmet Zehir@ahmetz21 Nov 2019
Happy to share our first @biorxivpreprint on how oncologic therapy shapes the fitness landscape of clonal hematopoiesis in cancer patients. Fantastic team effort between @KellyLBolton, @RPtash, @tgao2018 and @PapaemmanuilLab with support from many others! bit.ly/34acSJL
3
20
5
58
Ryan N. Ptashkin retweeted
Alex Cagan@ATJCagan5 Nov 2019
Michael Berger on tumour profiling to identify therapeutic biomarkers and guide clinical care in cancer #EMBLCanGen
5
20
1
56
Still smiling (and wobbling) from a great #TCSNYCMarathon weekend and #1 cheer squad! Thanks to everyone that came out and helped raise over $6M! for @FredsTeam
3
1
16
1
Load more